Department of Thoracic Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan.
Int J Clin Oncol. 2012 Jun;17(3):218-24. doi: 10.1007/s10147-011-0277-4. Epub 2011 Jun 30.
Although prophylactic cranial irradiation (PCI) in limited-stage (LS) small cell lung cancer (SCLC) patients who are surgically resected and treated with adjuvant chemotherapy is considered to be a reasonable treatment option, the efficacy of PCI for those patients remains unclear.
The records of 28 patients with SCLC undergoing curative surgery at the Aichi Cancer Center Hospital between 1995 and March 2008 were retrospectively reviewed to assess patterns of relapse and overall survival.
The patients were 27 men and 1 woman. Eight patients underwent induction chemotherapy. Fourteen patients (50%) had pathologic stage (p-stage) I disease, 7 patients (25%) had p-stage II, and 7 patients (25%) had p-stage III. Nineteen patients underwent adjuvant chemotherapy and one patient received adjuvant chemoradiotherapy. There were a total of 13 deaths and 8 were disease-related. Most patients developed hematogenous distant metastases before their death. The 5-year overall probability of survival was 47%. Ten (36%) of the 28 patients had a relapse. Two had a local relapse alone, one patient had combined local and distant relapses, and seven patients had distant metastases alone as their first site of failure. Four patients with p-stage II/III disease developed brain metastases with a cumulative incidence at 1 and 2 years of 25 and 36%, respectively.
Our retrospective study suggested that PCI might have a role in surgically resected patients with p-stage II/III SCLC because of their relatively high frequency of brain metastasis.
对于接受手术切除和辅助化疗治疗的局限性小细胞肺癌(LS-SCLC)患者,预防性颅脑照射(PCI)被认为是一种合理的治疗选择,但 PCI 对这些患者的疗效尚不清楚。
回顾性分析了 1995 年至 2008 年 3 月在爱知县癌症中心医院接受根治性手术的 28 例 SCLC 患者的病历,以评估复发模式和总生存率。
患者均为男性,共 27 例,1 例为女性。8 例患者接受了诱导化疗。14 例(50%)患者为病理分期(p 期)I 期疾病,7 例(25%)为 p 期 II 期疾病,7 例(25%)为 p 期 III 期疾病。19 例患者接受了辅助化疗,1 例患者接受了辅助放化疗。共有 13 例死亡,其中 8 例与疾病相关。大多数患者在死亡前出现血行远处转移。5 年总生存率为 47%。28 例患者中有 10 例(36%)复发。2 例患者仅出现局部复发,1 例患者出现局部和远处复发,7 例患者仅出现远处转移作为首次失败部位。7 例 p 期 II/III 期疾病患者出现脑转移,其累积发生率在 1 年和 2 年分别为 25%和 36%。
我们的回顾性研究表明,对于 p 期 II/III 期 SCLC 患者,PCI 可能具有一定作用,因为这些患者脑转移的发生率相对较高。